International Journal of Rheumatology / 2015 / Article / Tab 1 / Research Article
Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East Table 1 Demographics and baseline disease characteristics.
Tocilizumab Patient characteristics Sex, (%) Female 78 (82.1) Male 17 (17.9) Race, (%) White 69 (72.6) Black 3 (3.2) Other 23 (24.2) Smokers, (%) 4 (4.2) Age, years, mean (SD) 44.9 (13.7) BMI, kg/m2 , mean (SD) 28.1 (5.4) Disease characteristics DAS28, mean (median [range]) 6.1 (5.8 [3.4, 8.8]) Tender joint count, mean 13.28 Swollen joint count, mean 8.6 HAQ-DI, mean (SD) 1.6 (0.6) CRP, mg/L, mean (SD) 26.9 (34.4) ESR, mm/h, mean (SD) 45.3 (29.2) Concomitant medication used by >10%, (%) Immunosuppressants 86 (90.5) Methotrexate 83 (87.4) Prednisolone 47 (49.5) Methylprednisolone 6 (6.3) Prednisone 7 (7.4) aTNF agent (etanercept or adalimumab) 5 (5.3) Antianemia preparations 65 (68.4) Anti-inflammatory and antirheumatic products 50 (52.6) Vasoprotectives 46 (48.4) Antiprotozoals 37 (38.9) Mineral supplements 35 (36.8) Vitamins 30 (31.6) Antidiarrheals, intestinal anti-inflammatory/anti-infective agents 29 (30.5) Drugs for acid-related disorders 27 (28.4) Lipid-modifying agents 21 (22.1) Drugs for treatment of bone diseases 14 (14.7) Agents acting on the renin-angiotensin system 12 (12.6) Drugs used in diabetes 11 (11.6)
BMI, body mass index; CRP, C-reactive protein; DAS28, Disease Activity Score based on 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; SD, standard deviation.